Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
BioNTech SE et al. Inter Partes Review
-
March 14, 2025
PTAB Explains Why It Invalidated Moderna's COVID Vax Patents
The Patent Trial and Appeal Board has unsealed its decisions finding that Pfizer and BioNTech had shown that all the challenged claims of two Moderna COVID-19 vaccine patents are invalid, saying the success of the vaccine didn't outweigh strong evidence that the inventions were obvious.
-
March 05, 2025
Pfizer, BioNTech Get PTAB To Invalidate Moderna Vaccine IP
The Patent Trial and Appeal Board handed a massive victory to Pfizer and BioNTech on Wednesday, as it invalidated two Moderna patents covering its Spikevax COVID-19 vaccine, which the challengers stand accused of infringing.
-
December 10, 2024
PTAB Grapples With MRNA History In COVID Vax Dispute
Attorneys for Pfizer, BioNTech and Moderna squared off at the Patent Trial and Appeal Board on Tuesday, disputing whether experts would have found mRNA-based vaccines worth pursuing before the 2019 coronavirus outbreak.
-
December 05, 2024
IP Forecast: PTAB To Hear Pfizer Fight Over COVID-19 Patents
Pfizer heads to an administrative board at the U.S. Patent and Trademark Office next week to argue Moderna should not have been issued patents covering "a basic idea" like using mRNA to fight the COVID-19 virus. Here's a spotlight on that case — plus all the other major intellectual property matters on deck in the coming week.
-
March 20, 2024
PTAB To Analyze Moderna COVID Vaccine Patents
The Patent Trial and Appeal Board has agreed to review two Moderna COVID-19 vaccine patents challenged by rivals Pfizer and BioNTech as having "unimaginably broad claims directed to a basic idea that was known long before."
-
January 30, 2024
Pfizer Says Moderna Telling FDA One Thing, PTAB Another
Pfizer has told the Patent Trial and Appeal Board that the language Moderna used to quickly gain approval from the U.S. Food and Drug Administration for its COVID-19 vaccines should doom its efforts to defend its patents at the board, accusing it of pursuing a "litigation-driven one-eighty."
-
January 16, 2024
Pfizer Calls Moderna 'Willfully Naïve' In Covid Vax IP Fight
Pfizer and BioNTech have told the Patent Trial and Appeal Board not to rely on the timing of district court patent litigation to reject their challenges to a pair of Moderna COVID vaccine patents, arguing that the company relied on "cherry-picked data" and is acting "willfully naïve."
-
December 11, 2023
Moderna Says Pfizer COVID Vax Patent Challenges Fail Fintiv
Moderna has urged the Patent Trial and Appeal Board not to review its COVID-19 vaccine patents challenged by rivals Pfizer and BioNTech, saying a related district court trial will likely end before the board's decision is due, and the petitions don't show that the patents are invalid.
-
August 28, 2023
Pfizer Takes Aim At Moderna COVID Vaccine Patents At PTAB
Pfizer and BioNTech on Monday filed Patent Trial and Appeal Board challenges to two of the three Moderna COVID-19 vaccine patents they have been accused of infringing, saying the "unimaginably broad" claims of the patents are invalid as anticipated and obvious.